Oliva launches GeneIQ – India’s First DNA-Based Derma Clinic Application
Over 130 genes and 150 traits analysed to provide personalised skin careGeneIQ…
AV-Comparatives Publishes 2025 Endpoint Prevention & Response (EPR) Test – The Most Comprehensive Enterprise Cybersecurity Evaluation to Date
INNSBRUCK, Austria, Sept. 22, 2025 /PRNewswire/ -- AV-Comparatives, the leading independent cybersecurity…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
IOC Executive Board approves Olympic medal reallocations for Vancouver 2010 and Sochi 2014
19 September 2025 - The International Olympic Committee (IOC) Executive Board (EB) today took the…
Five Point Announces Expiration and Results of Cash Tender Offer for Any and All Outstanding 10.500% Initial Rate Senior Notes Due 2028
IRVINE, Calif.--(BUSINESS WIRE)--Five Point Holdings, LLC (“Five Point”) (NYSE: FPH) announced today…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
No Difference in Transplant Outcomes Seen for Patients Unlikely to Find a Matched Unrelated Donor When a Donor Search Prognosis Strategy is Used
Published in the Journal of Clinical Oncology, results showed no difference in…
Investing in Futures: Education Cannot Wait Reaches 14 Million Children in Crises Worldwide
New ECW Results Report highlights transformative education outcomes for children and adolescents…
Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…